[1]ARMSTRONG DK,ALVAREZ RD,BAKKUM-GAMEZ JN,et al.NCCN guidelines insights:ovarian cancer,version 1.2019［J］.J Natl Compr Canc Netw，2019，17(8):896-909.
[2]JIANG Y,HOU G,WU F,et al.The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment:A retrospective clinical study［J］.Medicine (Baltimore)，2020，99(8):e19228.
[3]卢淮武,霍楚莹,林仲秋.《2019 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读［J］.中国实用妇科与产科杂志,2019,35(05):52-62.
LU HW,HUO CY,LIN ZQ.Interpretation of "2019 NCCN clinical practice guidelines for ovarian cancer including fallopian tube cancer and primary peritoneal cancer (first edition)"［J］.Chinese Journal of Practical Gynecology and Obstetrics,2019,35(05):52- 62.
[4]MIYANAGA S,HORIKAWA N,HAYASHI K,et al.A case of multiple laparoscopic surgeries performed for disseminated peritoneal recurrence of primary peritoneal carcinoma［J］.Gan To Kagaku Ryoho,2018,45(13):1809-1811.
[5]KATO K,MATSUURA M,TAKESHIMA N.Secondary debulking surgery for isolated para-aortic nodal recurrence in endometrial cancer requiring partial resection of the inferior vena cava［J］.Gynecol Oncol,2015,139(3):580-581.
[6]KATO K,OKAMOTO S,OTA E,et al.Secondary debulking surgery for para-aortic nodal recurrence in endometrial cancer requiring circumferential resection of the inferior vena cava［J］.Gynecol Oncol,2018,149(1):221-222.
[7]NAKAMURA K,KAJIYAMA H,UTSUMI F,et al.Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas［J］.Mol Clin Oncol,2018,8(3):499-503.
[8]JAMIESON A,SYKES P,EVA L,et al.Subtypes of stage Ⅳ ovarian cancer;response to treatment and patterns of disease recurrence［J］.Gynecol Oncol,2017,146(2):273-278.
[9]FELSINGER M,MINAR L,WEINBERGER V,et al.Secondary cytoreductive surgery-viable treatment option in the management of platinum-sensitive recurrent ovarian cancer［J］.Eur J Obstet Gynecol Reprod Biol,2018,228:154-160.
[10]FERRERO A,DITTO A,GIORDA G,et al.Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer:a multicenter study［J］.Eur J Surg Oncol,2014,40(7):891-898.
[11]TAKAHASHI A,KATO K,MATSUURA M,et al.Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian,tubal,or peritoneal carcinoma:A propensity score-matched analysis of 112 consecutive patients［J］.Medicine (Baltimore),2017,96(37):e8006.
[12]MARCHETTI C,ROSATI A,SCALETTA G,et al.Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance:Still getting any benefit? A case-control study［J］.Gynecol Oncol,2019,155(3):400-405.
[13]ROSE PG,JAVA JJ,MORGAN MA,et al.Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer:An NRG Oncology/Gynecologic Oncology Group study［J］.Gynecol Oncol,2016,143(3):511-515.
[14]COLEMAN RL,SPIRTOS NM,ENSERRO D,et al.Secondary surgical cytoreduction for recurrent ovarian cancer［J］.N Engl J Med,2019,381(20):1929-1939.
[15]DU BOIS A,VERGOTE I,FERRON G,et al.Randomized controlled phase Ⅲ study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer:AGO DESKTOP Ⅲ/ENGOT ov20［J］.J Clin Oncol,2017,35:5501.
[16]KATSNELSON M,HWANG WT,TAHIROVIC E,et al.Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer［J］.J Obstet Gynaecol,2018,38(3):395-401.
[17]SHARMA V,NAIK RD,VANIDASSANE I.Secondary surgical cytoreduction for recurrent ovarian cancer［J］.N Engl J Med,2020,382(7):685.
[18]PAULINO E.Secondary surgical cytoreduction for recurrent ovarian cancer［J］.N Engl J Med，2020，382(7):685-686.
[19]COLEMAN RL.Secondary surgical cytoreduction for recurrent ovarian cancer［J］.N Engl J Med,2020,382(7):686.
[20]AMIT A,HODES A,LAVIE O,et al.The role of （18）F-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer［J］.Surg Oncol,2017,26(4):347-351.
[21]诸一鸣,陈平,朱滔,等.PET/CT摄取指标与复发卵巢癌患者二次减瘤效果及预后的关系分析［J］.浙江医学,2019,41(08):46-49.
ZHU YM,CHEN P,ZHU T,et al.Analysis of the relationship between PET/CT uptake index and secondary tumor reduction effect and prognosis in patients with recurrent ovarian cancer［J］.Zhejiang Medicine,2019,41(08):46-49.
[22]PENG P,ZHU ZH,ZHONG ZJ,et al.Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer［J］.Br J Radiol,2015,88(1052):20150109.
[23]VARGAS HA,BURGER IA,GOLDMAN DA,et al.Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery［J］.Eur Radiol,2015,25(11):3348-3353.
[24]PARASHKEVOVA A,SEHOULI J,RICHTER R,et al.Preoperative CA-125 value as a predictive factor for postoperative outcome in first relapse of platinum-sensitive serous ovarian cancer［J］.Anticancer Res,2018,38(8):4865-4870.
[25]GOMEZ-RUIZ OJ,GONZALEZ-GIL A,GIL J,et al.Peritoneal surface disease severity score (PSDSS),AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC［J］.Clin Exp Metastasis,2019,36(5):433-439.
[26]LAGA T,LAMBRECHTS S,LAENEN A,et al.Positive DESKTOP and tian scores systems are adequate to predict optimal (r0)secondary debulking surgery in ovarian cancer,but a negative score does not preclude secondary surgery［J］.Int J Gynecol Cancer,2018,28(4):721-728.
[27]LAAS E,LUYCKX M,DE CUYPERE M,et al.Secondary complete cytoreduction in recurrent ovarian cancer:benefit of optimal patient selection using scoring system［J］.Int J Gynecol Cancer,2014,24(2):238-246.
[28]SO M,MIYAMOTO T,MURAKAMI R,et al.The efficacy of secondary cytoreductive surgery for recurrent ovarian,tubal,or peritoneal cancer in Tian-model low-risk patients［J］.J Gynecol Oncol,2019,30(6):e100.
[29]BOGANI G,TAGLIABUE E,SIGNORELLI M,et al.A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery:predictors- and nomogram-based analyses［J］.J Gynecol Oncol,2018,29(3):e40.
[30]王丽梅.二次肿瘤细胞减灭术在复发性卵巢癌预后的相关临床因素分析［J］.实用妇科内分泌电子杂志,2018,005(036):137-138.
WANG LM.Analysis of clinical factors related to the prognosis of recurrent ovarian cancer in secondary cytoreductive surgery［J］.Practical Journal of Gynecology Endocrinology,2018,005(036):137-138.
[31]VAN DE LAAR R,KRUITWAGEN RF,ZUSTERZEEL PL,et al.Correspondence:premature stop of the soccer trial,a multicenter randomized controlled trial on secondary cytoreductive surgery:netherlands trial register number:NTR3337［J］.Int J Gynecol Cancer,2017,27(1):2.
[32]MINAGUCHI T,SATOH T,MATSUMOTO K,et al.Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian,tubal,and peritoneal cancers［J］.Int J Clin Oncol,2016,21(3):573-579.
[33]GALLOTTA V,CONTE C,GIUDICE MT,et al.Secondary laparoscopic cytoreduction in recurrent ovarian cancer:a large,single-institution experience［J］.J Minim Invasive Gynecol,2018,25(4):644-650.
[34]GALLOTTA V,NERO C,LODOLI C,et al.Laparoscopic splenectomy for secondary cytoreduction in ovarian cancer patients with localized spleen recurrence:feasibility and technique［J］.J Minim Invasive Gynecol,2016,3(3):425-428.
[35]BACALBASA N,BALESCU I,DIMA S,et al.Extended pelvic resections as part of secondary cytoreduction for relapsed ovarian adenocarcinoma［J］.In Vivo,2020,34(1):397-400.
[36]PAIK ES,LEE YY,KIM TJ,et al.Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer［J］.J Gynecol Oncol，2016，27(3):e24.
[37]ERIKSSON AGZ,GRAUL A,YU MC,et al.Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma:Perioperative and oncologic outcomes［J］.Gynecol Oncol，2017，146(2):263-267.
[38]PETRILLO M,ZUCCHETTI M,CIANCI S,et al.Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer:a prospective study［J］.J Gynecol Oncol，2019，30(4):e59.
[39]BATISTA TP,KUSAMURA S.Comments on:Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer:a prospective study［J］.J Gynecol Oncol，2019，30(6):e111.
[40]PERGIALIOTIS V,ANDROUTSOU A,PAPOUTSI E,et al.Survival outcomes of ovarian cancer patients treated with secondary cytoreductive surgery for isolated lymph node recurrence:A systematic review of the literature［J］.Int J Surg，2019，69:61-66.
[41]FAN XM,ZHANG J,NIU SH,et al.Secondary cytoreductive surgery in recurrent epithelial ovarian cancer:A prognostic analysis with 103 cases［J］.Int J Surg，2017，38:61-66.
[42]JEONG SY,CHOI CH,KIM TJ,et al.Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer［J］.J Ovarian Res，2019，13(1):1.
[43]KUMAR S,SRINIVASAN A,PHILLIPS A,et al.Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer［J］.J Obstet Gynaecol，2020，40(6):849-855.
[44]GASPARRI ML,GRANDI G,BOLLA D,et al.Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer［J］.J Cancer Res Clin Oncol，2016，142(7):1509-1520.
[45]TRAN AQ,COHEN JG,LI AJ.Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer［J］.Gynecol Oncol，2015，138(2):263-266.
[46]ANGIOLI R,CAPRIGLIONE S,ALOISI A,et al.A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (sec-score):a single-centre,controlled study for preoperative patient selection［J］.Ann Surg Oncol，2015，22(13):4217-4223.